Targeting glycosylated PD-1 induces potent anti-tumor immunity

Immunotherapies targeting programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) immune checkpoints represent a major breakthrough in cancer treatment. PD-1 is an inhibitory receptor expressed on the surface of activated T-cells that dampens T-cell receptor (TCR)/CD28 si...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res
Hlavní autoři: Sun, Linlin, Li, Chia-Wei, Chung, Ezra M., Yang, Riyao, Kim, Yong-Soo, Park, Andrew H., Lai, Yun-Ju, Yang, Yi, Wang, Yu-Han, Liu, Jielin, Qiu, Yufan, Khoo, Kay-Hooi, Yao, Jun, Hsu, Jennifer L., Cha, Jong-Ho, Chan, Li-Chuan, Hsu, Jung-Mao, Lee, Heng-Huan, Yoo, Stephen S., Hung, Mien-Chie
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7272274/
https://ncbi.nlm.nih.gov/pubmed/32156778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-3133
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky